Lyme disease testing market seen reaching $16.46B by 2030

The Lyme disease testing market is projected to grow from $10.68 billion in 2025 to $16.46 billion by 2030, driven by rising tick-borne illness cases, wider use of rapid diagnostics and more funding for surveillance. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Lyme disease testing is becoming a bigger public health and diagnostics market as tick-borne illness exposure rises and early detection remains critical. - The market outlook points to sustained demand for laboratory tests, home tests and faster point-of-care tools. - The forecast suggests more investment opportunities for diagnostics companies, labs and health systems focused on tick-borne disease management.

What happened: - The Lyme disease testing market is projected to increase from $10.68 billion in 2025 to $11.67 billion in 2026. - The market is expected to reach $16.46 billion by 2030. - The forecast implies a 9.3% compound annual growth rate in 2026 and a 9.0% compound annual growth rate through 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Lyme disease testing is used to detect infection by Borrelia burgdorferi, the bacterium transmitted mainly through tick bites. - The tests are designed to help diagnose patients with symptoms such as fever, fatigue and the bull’s-eye rash. - Market growth has been supported by higher Lyme disease incidence, low awareness of early detection, continued reliance on traditional serological tests, more hospital-based diagnostic activity and greater research into tick-borne diseases. - The market outlook highlights growing use of AI-assisted diagnostic tools, home-testing kits, multi-disease testing panels, government funding for tick-borne disease monitoring and cloud-based laboratory data management systems. - The report expects broader rollout of point-of-care testing, more home-based Lyme diagnostics, multi-pathogen tick-borne disease panels, rapid test kits and more customized diagnostic protocols. - Rising tick-borne illness prevalence is also driving demand for testing. - Climate change has expanded the geographic range of ticks and increased human exposure. - The CDC reported more than 89,000 Lyme disease cases in 2023 in March 2025. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, plus updated graphics and tables. - The press release includes links to download a sample report and view the full market report.

Between the lines: - The forecast points to a market moving beyond conventional lab testing toward faster, more distributed and more automated diagnostics. - The combination of climate-driven tick expansion and more public health attention suggests sustained pressure for better screening and surveillance. - Faster growth in Asia-Pacific may reflect a broader buildout of diagnostic capacity and rising awareness outside the market’s traditional strongholds.

What's next: - The market is likely to keep shifting toward rapid testing, home use and multi-pathogen panels as adoption broadens. - Government monitoring programs and lab-data systems may become more important as Lyme surveillance and diagnosis become more digital. - Competitive focus will likely center on accuracy, speed and ease of use in both clinical and consumer settings.